Timothy Scannell left the role of Director at NovoCure Ltd, effective September 2, 2026. As of November 10, 2026, NovoCure Ltd has reported 2 leadership change filings to the SEC under Item 5.02 of Form 8-K, from April 24, 2026 to September 9, 2026, naming 1 departure (Form 8-K, September 9, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like NovoCure Ltd? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
NovoCure Ltd reported changes in 2 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-04-24 to 2026-09-09. They name 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as NovoCure Ltd files it.
Also on the record for NovoCure Ltd
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| November 9, 2026 | Stake report, Schedule 13G/A, by Soleus Capital Master Fund, L.P. | 8.1% of the class | 5%+ stakes | Source |
| May 8, 2026 | Stake report, Schedule 13G/A, by Soleus Capital Master Fund, L.P. | 9.1% of the class | 5%+ stakes | Source |
| April 28, 2026 | Stake report, Schedule 13G, by Vanguard Portfolio Management | 5.57% of the class | 5%+ stakes | Source |
| March 26, 2026 | Stake report, Schedule 13G/A, by The Vanguard Group | — | 5%+ stakes | Source |
| February 12, 2026 | Stake report, Schedule 13G/A, by Soleus Capital Master Fund, L.P. | 7.6% of the class | 5%+ stakes | Source |
| November 13, 2025 | Stake report, Schedule 13G/A, by Capital World Investors | 1.8% of the class | 5%+ stakes | Source |
| November 7, 2025 | Stake report, Schedule 13G/A, by Soleus Capital Master Fund, L.P. | 8.6% of the class | 5%+ stakes | Source |
| August 13, 2025 | Stake report, Schedule 13G, by Capital World Investors | 5.7% of the class | 5%+ stakes | Source |
| August 5, 2025 | Stake report, Schedule 13G/A, by Soleus Capital Master Fund, L.P. | 6.2% of the class | 5%+ stakes | Source |
| July 7, 2025 | Stake report, Schedule 13G/A, by Capital International Investors | — | 5%+ stakes | Source |
Selling to them or working with them? See who runs NovoCure Ltd now and the warning signs.
Free to see. No signup.
Keep reading
More on NovoCure Ltd and the records around it.
NovoCure Ltd elsewhere on the record
- 5%+ stake filings Nov 2026
- Who owns it
Companies that share a holder
- Soleus Capital Master Fund, L.P. also filed stake reports on 24 other companies: Beta Bionics, Inc. (Nov 2026), Evolus, Inc (Nov 2026), INSPIRE MEDICAL SYSTEMS, INC. (Nov 2026)
- Capital International Investors also filed stake reports on 96 other companies: Aurora Innovation, Inc. (Nov 2026), Arxis, Inc. (Aug 2026), Astronics Corp. (Aug 2026)
- Capital World Investors also filed stake reports on 125 other companies: New Fortress Energy Inc. (Oct 2026), Aura Minerals Inc. (Oct 2026), Skyworks Solutions, Inc. (Oct 2026)
Watch NovoCure Ltd
Get an email when NovoCure Ltd files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on NovoCure Ltd?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on NovoCure Ltd: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on NovoCure Ltd covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
12 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-09-09 | Out | Director | 2026-09-02 | 8-K, 2026-09-09 | |
| 2026-04-24 | Reported | not named in the filing | 8-K/A, 2026-04-24 |
Who leads NovoCure Ltd, as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Director: Timothy Scannell, departure reported, effective 2026-09-02 (filed 2026-09-09). No successor is named in these filings.
New leaders reset buying decisions — get the Full Report on NovoCure Ltd: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Director at NovoCure Ltd, with the record behind each one.
Find candidates like Director at NovoCure LtdEvery change, in the filing's words
Departing: Timothy Scannell, Director, effective 2026-09-02
(b) Timothy Scannell, a current director of NovoCure Limited (the "Company"), has retired from the Board and his seat was formally vacated pursuant to the Company's Articles of Association effective September 2, 2026.
- Mr. Scannell's retirement from the Board after five years of distinguished service did not result from any disagreement with the Company or its management.
Reported
Leonard Employment Agreement In connection with his appointment as Chief Executive Officer, on April 20, 2026, Mr. Leonard entered into a new employment agreement with a subsidiary of the Company (the "Leonard Employment Agreement"), effective January 1, 2026.
- Under the Leonard Employment Agreement, Mr. Leonard will receive an annual base salary of CHF 750,000 per year.
- In addition, Mr. Leonard is eligible to receive a discretionary annual cash bonus having a target of 90% of his annual base salary based on achievement of performance goals set by the Company's Board of Directors or committee thereof (the "Board"), in their sole discretion, and further subject to his continued employment through the payment date.
- Mr. Leonard is generally eligible to participate in Company's 2024 Omnibus Incentive Plan as determined by the Board.
- Further, Mr. Leonard is eligible to participate in the employee benefits generally provided to similarly-situated executive employees, subject to the satisfaction of any eligibility requirements.
- He will also receive relocation expense reimbursement per the Company's policy from the U.S. to Switzerland and COBRA expense reimbursement for six months for continuation of his and his family's health insurance benefits covering the transition from the U.S. to Swiss healthcare payment systems (in each case grossed up for taxes).
Tools for this story
Each opens in a new tab, filled in for NovoCure Ltd. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.